# Management of Complete Hydatidiform Mole

→ Complete mole: **abnormal proliferation** of trophoblastic tissue with **no fetal parts**
→ Karyotype: **46,XX or 46,XY**, all paternal origin
→ Risk of progression to **GTN** (invasive mole/choriocarcinoma)

## I. Pre-Evacuation Management

### 1. Clinical Assessment

- Assess symptoms: bleeding, vomiting, anemia, vitals
- Check **uterine size**, presence of **theca lutein cysts** (large ovaries)

### 2. Baseline Investigations

- **Serum β-hCG**
- **Full blood count**, blood grouping & cross-match
- **Coagulation profile** (for risk of DIC)
- **Liver & renal function tests**
- **Thyroid function test** (β-hCG cross-reactivity)
- **Chest X-ray** (to screen for lung metastasis)

---

## II. Evacuation of Mole (Definitive Treatment)

### 1. Method:

- **Suction Evacuation (Manual/Electric Vacuum Aspiration)**

  - Preferred over curettage (less trauma)
  - Under **oxytocin cover** to reduce bleeding

### 2. Avoid:

- **Medical abortion** (risk of incomplete evacuation, bleeding)
- **Routine hysterectomy**, except in:

  - Age > 40 & completed family
  - Severe bleeding
  - Suspicion of invasive mole

### 3. Anti-D Immunoglobulin

- Given to **Rh-negative women** after evacuation

---

## III. Post-Evacuation Monitoring

### 1. Histopathology

- Mandatory for diagnosis confirmation
- Rules out coexistent carcinoma or partial mole

### 2. Serial β-hCG Monitoring

| Frequency                                        | Purpose                    |
| ------------------------------------------------ | -------------------------- |
| **Weekly** until normal for 3 consecutive weeks  | Ensure complete resolution |
| **Monthly** for **6 months** after normalisation | Monitor for recurrence/GTN |

> **β-hCG plateau or rise → suspect GTN**.

---

## IV. Indications for Chemotherapy

### Start Chemotherapy if:

| Indication                                        | Explanation                  |
| ------------------------------------------------- | ---------------------------- |
| **β-hCG plateau** ≥4 values over 3 weeks          | Indicates persistent disease |
| **Rising β-hCG** over 2 weeks                     | Suggests active trophoblast  |
| **β-hCG detectable >6 months** after evacuation   | GTN diagnosis                |
| **Histology shows choriocarcinoma/invasive mole** | High risk of metastasis      |
| **Metastases (lungs, brain, liver)**              | Confirmed GTN                |
| **Heavy bleeding after evacuation**               | Suggests invasive mole       |

---

## V. Chemotherapy Regimens

### 1. Low-Risk GTN (FIGO score ≤6)

- **Single-agent chemotherapy**

| Drug            | Dose                                                                 | Schedule                 |
| --------------- | -------------------------------------------------------------------- | ------------------------ |
| `Methotrexate`  | 50 mg IM on days 1, 3, 5, 7 + folinic acid rescue on days 2, 4, 6, 8 | Every 2 weeks            |
| **or**          | 1 mg/kg IM weekly                                                    | until β-hCG normalises   |
| `Actinomycin D` | 1.25 mg/m² IV every 2 weeks                                          | Alternative if MTX fails |

---

### 2. High-Risk GTN (FIGO score ≥7)

- **Multi-agent chemotherapy (EMA-CO)**

| Regimen | Drugs                                    |
| ------- | ---------------------------------------- |
| `EMA`   | Etoposide + Methotrexate + Actinomycin D |
| `CO`    | Cyclophosphamide + Vincristine (Oncovin) |

> Given in cycles until **normal β-hCG x 3 weeks**, then 1–2 additional cycles

---

## VI. Follow-Up Duration

- **After Complete Mole**:
  - **Weekly β-hCG until negative x3**
  - **Then monthly for 6 months**
- **After Chemotherapy for GTN**
  - Monthly β-hCG for **12 months (low-risk)**
  - For **24 months (high-risk)**

---

## VII. Reasons for Prolonged Follow-Up

- Early detection of **GTN recurrence**
- Avoids delay in retreatment
- β-hCG is **highly sensitive** marker
- Risk persists especially in high-risk patients

---

## VIII. Contraception Advice

| Time                                                  | Method                                        |
| ----------------------------------------------------- | --------------------------------------------- |
| **During follow-up**                                  | **Barrier or hormonal (OCP)** allowed         |
| → Prevent pregnancy that may confuse β-hCG monitoring |                                               |
| **Avoid**                                             | IUD (until uterus involuted and β-hCG normal) |
| **Future pregnancy**                                  | Safe **after 6–12 months** of normal β-hCG    |

---

## Summary Table

| Component                | Management                                        |
| ------------------------ | ------------------------------------------------- |
| **Definitive Treatment** | Suction evacuation ± oxytocin                     |
| **Monitoring**           | Weekly then monthly β-hCG for 6 months            |
| **Chemo Indications**    | Rising or plateauing β-hCG, metastasis, histology |
| **Low-Risk Chemo**       | Methotrexate ± folinic acid                       |
| **High-Risk Chemo**      | EMA-CO                                            |
| **Contraception**        | OCP/Barrier; avoid IUD                            |
| **Pregnancy allowed**    | After 6–12 months of normal β-hCG                 |
